CN107937538A - Diagnosis of glioma marker circ1:201817088 | 201817285 and application - Google Patents
Diagnosis of glioma marker circ1:201817088 | 201817285 and application Download PDFInfo
- Publication number
- CN107937538A CN107937538A CN201711454282.2A CN201711454282A CN107937538A CN 107937538 A CN107937538 A CN 107937538A CN 201711454282 A CN201711454282 A CN 201711454282A CN 107937538 A CN107937538 A CN 107937538A
- Authority
- CN
- China
- Prior art keywords
- diagnosis
- glioma
- circ1
- excretion body
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to biological technical field, discloses diagnosis of glioma marker circ1:201817088 | 201817285 and application.In the present invention, circ1 in patients with gliomas serum excretion body is found first:201817088 | 201817285 expression is significantly raised compared to control group (p=0.003), ROC analyses then show that it has higher diagnostic value (AUC=0.937 to glioma, P=0.004, sensitivity and specificity are respectively 85.7% and 88.9%).Therefore by detecting circ1 in patients with gliomas serum excretion body:201817088 | 201817285 expression, can make patients with gliomas early stage, quick Noninvasive diagnosis.
Description
Technical field
The invention belongs to biological technical field, is related to a kind of serum circRNA markers for diagnosis of glioma
circ1:201817088 | 201817285 and detect the marker reagent be used to prepare the application of diagnosis of glioma preparation,
Also kit.
Background technology
Glioma is the brain tumor disease that adult takes place frequently the most, accounts for the 40.49% of intracranial tumors.Since making a definite diagnosis,
The Patients with gliomas the average survival time service life is no more than 5 years.For this evil high with inhereditary material correlation of diagnosis and treatment glioma
Property disease, it is necessary to it is horizontal in molecular biology, explore its pathogenesis in terms of hereditary information expression.Presently colloid
Though the diagnostic and therapeutic method of knurl is in and continuously improves the stage, patients with gliomas survival rate is not significantly improved.Colloid
Knurl diagnosis is still within the experience sexual stage based on clinical, pathology and iconography information, and one after diagnosing, absolutely mostly
Number is middle and advanced stage, and postoperative survival rate allows of no optimist.Therefore, diagnosis of glioma marker is found to sieve people at highest risk
Look into, and correspondingly select rational successive treatment scheme, improve survival rate, be neuroscience field Task urgently to be resolved hurrily.
Circular rna is a kind of extensive and is diversely present in mammalian cell, has controlling gene expressional function
Endogenous non-coding RNA molecule, has covalence closed loop configuration, is widely present in various cells, and after
The current research hot spot of microRNA (miRNA) RNA families afterwards.In recent years, with the extensive use and life of deep sequencing technology
The fast development of thing physics and informatics technology, it has been found that the transcript of many extrons of the mankind non-linearly can reversely be cut
Connect or circular rna is formed by gene rearrangement, and they account for sizable ratio in all montage transcripts.In recent years
Also gradually find also to contain substantial amounts of circular rna in excretion body, may play a significant role.Excretion body refers to contain complexity
The small film bubble (30-150nm) of RNA and protein, now, it refers in particular to plate-like vesica of the diameter in 40-100nm.Nineteen eighty-three, excretion
Body is found in sheep granulophilocyte first, and Johnstone is named as " exosome " within 1987.Research in recent years is shown
Show, excretion body is the important molecule of cell and cell-cell communication, participates in many physiology and pathologic process.Not only wrapped in excretion body
Containing protein component, further include some RNA components, as Microrna (micro RNA, miRNA), long-chain non-coding RNA and
MRNA, circular rna (circular RNA, circRNA).These RNA entrained by excretion body are referred to as excretion body source RNA,
With complete sequential structure and bioactivity, it is expected to, as liquid biopsy molecular marker, on accurate medical development have
Bright prospect.
The content of the invention
The present invention first purpose be:A kind of serum excretion body circRNA markers for diagnosis of glioma are provided.
Main contents include:A kind of serum excretion body circRNA markers circ1 for diagnosis of glioma:
201817088 | 201817285, its sequence such as SEQ NO:Shown in 1.The circRNA is located on No. 1 chromosome of the mankind, entirely
Long 198bp.
Second object of the present invention is to provide detection circRNA markers expression quantity in serum excretion body
Application of the reagent in diagnosis of glioma preparation is prepared.
Third object of the present invention is to provide a kind of diagnosis of glioma kit, it can be measured in serum excretion body
Circ1:201817088 | 201817285 content.
The diagnosis of glioma kit, contains detection circ1:201817088 | the PCR of 201817285 contents draws
Thing.It is preferred that the sequence of primer such as SEQ NO:Shown in 2 and 3.
The diagnosis of glioma kit, except circ1:201817088 | outside 201817285 primer, also contain from blood
Excretion body is extracted in clear, by extracting RNA in excretion body and carrying out all reagents of reverse transcription and quantitative fluorescent PCR.
Including:
(1) reagent needed for serum excretion body is extracted:Total Exosome Isolation Reagent(from
Serum), can be bought by Invitrogen companies, article No. 4478360;
(2) reagent needed for excretion body RNA is extracted:Trizol reagents, chloroform, isopropanol, 75% ethanol, without enzyme water;
(3) reagent needed for reverse transcription:Random primer (Random Primer), without enzyme water, 5 × RT Buffer, three phosphorus
Soda acid base deoxynucleotide, RNase inhibitor, MMLV reverse transcriptases;
(4) reagent needed for quantitative fluorescent PCR:circ1:201817088 | 201817285 upstream and downstream primers, GAPDH internal references
Upstream and downstream primer, SYBR dyestuffs, without enzyme water.
The beneficial effects of the present invention are:
Circ1 in the serum excretion body of patients with gliomas is found first:201817088 | 201817285 compare normal serum
Excretion body is according to group significantly up-regulation (p=0.003).ROC curve is analysis shows that circ1:201817088 | 201817285 as biology
Label has glioma higher diagnostic value, and (AUC=0.937, sensitivity and specificity are respectively 85.7% He
88.9%).By application of the circular rna in diagnosis of glioma analysis, it can cause the more convenient standard of diagnosis of glioma
Really, conditions of patients is quick and precisely grasped for clinician, laid the foundation to improve clinical therapeutic efficacy, and it is potential to find to have
The new small molecule drug targets of therapeutic value provide help.
Brief description of the drawings
Fig. 1 analyzes circ1 for real-time fluorescence quantitative PCR:201817088 | 201817285 patients with gliomas serum with just
Differential expression in normal serum excretion body;
Fig. 2 is the circ1 that Roc analyzes serum excretion body source:201817088 | 201817285 pairs of glioma early diagnosis
Specificity, sensitivity.
Embodiment
The present invention is intended to further illustrate below in conjunction with embodiment, is not intended to limit the present invention.
First, research object
The serum sample of 40 patients with gliomas is provided by Xiang Ya hospitals, and 15 normal serum samples carry out community for the same period
The healthy individuals of disorder in screening.Sample for research is collected for the same period, sample, dispense, preservation condition it is consistent.
2nd, research method
1. the extracting of RNA in glioma/normal serum excretion body
Take 200 μ l of serum to be centrifuged 30 minutes in 2000g room temperature, supernatant liquor is extracted to 600 new μ l with micropipettor
Centrifuge tube, adds 40 μ l excretion bodies extracts reagent (Total Exosome Isolation Reagent (from serum), goods
Number 4478360, Invitrogen companies) gently turning upside down shakes up, and 4 DEG C are incubated 45 minutes.10000g room temperature after incubation
Centrifugation 10 minutes, discards supernatant, and gained precipitation is the excretion body in serum.200 μ l Trizol (MRC are added in precipitation
Company) precipitation is resuspended, suspension is moved to new 1.5ml tube manages, and mends Trizol to 1ml.15min is cracked on ice.Cracking knot
4 DEG C after beam, 12000rpm centrifugation 10min, supernatant moves to new tube pipes.Chlorination imitates 200 μ l in Tube, is shaken with hand
15-30s, places 5min, 4 DEG C, 12000rpm centrifuges 15min on ice;Carefully take upper strata aqueous phase to enter in new tube, add precooling
Isopropanol 0.5ml is mixed, and stands be more than 20min on ice, 4 DEG C, 12000rpm centrifugations 10min;Supernatant is abandoned, adds 75%DEPC water
Diluted ethanol 1ml is mixed, 4 DEG C, and 7500rpm centrifugation 5min, abandon supernatant, drying at room temperature 5-10min, adds no enzyme water 10 as far as possible
μ l dissolve RNA.- 80 DEG C of preservations, refrigerator temperature is recorded by laboratory technician daily.It is prepared by 2.cDNA
Reverse transcription reaction is carried out according to Reverse Transcriptase kit (Thermo companies) specification.Reaction cumulative volume is (total for 20 μ l
RNA10 μ l, Random primer 1 μ l, no 1 μ l, 5 × Reaction Buffer of enzyme water 4 μ l, RI 1 μ l, RT 1 μ l and
10mM dNTP 2μl)。
Component | Dosage/pipe |
Random reverse transcriptase primer (1 μM) | 1μl |
RNA samples | 10μl |
Without enzyme water | To 12μl |
Reverse transcription first step condition:65 DEG C 5 minutes
Reverse transcription second step program:25 DEG C 5 minutes, 42 DEG C 60 minutes, 70 DEG C 5 minutes.
3. real-time fluorescence quantitative PCR
(primer sequence is shown in SEQ NO to the specific primer synthesized using Han Heng biotechnologies (Shanghai) Co., Ltd.:2 and 3)
Carry out real-time quantitative PCR:Reverse transcription product is first diluted 10 times, is mixed.20 μ l reaction systems are as follows:
Component | Dosage/pipe |
SYBR Premix Ex Taq | 10μl |
Primer (10 μM) | 0.5μl |
CDNA products (after dilution) | 5μl |
Without enzyme water | To 20μl |
Real-time fluorescence quantitative PCR response procedures:95 DEG C 3 minutes, 40 circulation, 95 DEG C 10 seconds, 60 DEG C 30 seconds.
4. data analysis:Using 2-ΔΔCTRepresent the circ1 of glioma serum excretion body:201817088 | 201817285 phases
For the expression multiple of normal serum excretion body, wherein △ CT=CTSample–CTInternal reference, Δ Δ CT=Δs CTGlioma–ΔCTNormally.This reality
The analysis method that data use relative quantification is tested, (primer sequence is shown in SEQ NO to GAPDH as reference gene:4 and 5), data profit
Analyzed with software GraphPad Prism and SPSS 17.0.
3rd, result of study
1. the serum excretion body of patients with gliomas is to circ1:201817088 | 201817285 have obvious enrichment, and phase
Up-regulation (p=0.003) more notable than normal serum excretion body control group, specific data are as shown in Figure 1.
2.ROC tracing analysis shows circ1:201817088 | 201817285 have glioma as biomarker
(AUC=0.937, sensitivity and specificity are respectively 85.7% and 88.9%), and detailed results are shown in Fig. 2 for higher diagnostic value.
Sequence table
<110>Xiangya Hospital, Central-South China Univ.
<120>Diagnosis of glioma marker circ1:201817088 | 201817285 and application
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 198
<212> RNA
<213>Homo sapiens (Homo sapiens)
<400> 1
guccauggac agaaagcugc uugggaggac ccaguggaau ggguccggga cacacuuccc 60
uggccaucag cccaacaaga ccaaucaaag cuguaccacc ugcccccacc caccgugggc 120
ccucacagca uugccucacc ucccgaggau aggacaguca aagacagcac cccaaguucu 180
cuggacucag auccucug 198
<210> 2
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 2
cacagcattg cctcacct 18
<210> 3
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 3
cctcccaagc agctttct 18
<210> 4
<211> 19
<212> DNA
<213>Unknown (Unknown)
<400> 4
atcatcagca atgcctcct 19
<210> 5
<211> 18
<212> DNA
<213>Unknown (Unknown)
<400> 5
catcacgcca cagtttcc 18
Claims (6)
- A kind of 1. diagnosis of glioma marker circ1:201817088 | 201817285, its sequence such as SEQ NO:Shown in 1.
- 2. the reagent of marker expression quantity in serum excretion body described in test right requirement 1 is preparing diagnosis of glioma preparation In application.
- 3. a kind of diagnosis of glioma kit, it is characterised in that the circ1 in serum excretion body can be measured:201817088| 201817285 content.
- 4. diagnosis of glioma kit according to claim 3, it is characterised in that contain detection circ1:201817088| The PCR primer of 201817285 contents.
- 5. diagnosis of glioma kit according to claim 4, it is characterised in that the sequence of primer such as SEQ NO:2 and 3 It is shown.
- 6. according to the diagnosis of glioma kit described in claim 3 or 4 or 5, it is characterised in that except circ1:201817088| Outside 201817285 primer, also contain and excretion body is extracted from serum, by extracting RNA in excretion body and carrying out reverse transcription and glimmering All reagents of Fluorescent Quantitative PCR.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711454282.2A CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107937538A true CN107937538A (en) | 2018-04-20 |
CN107937538B CN107937538B (en) | 2020-06-30 |
Family
ID=61940619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711454282.2A Active CN107937538B (en) | 2017-12-28 | 2017-12-28 | Glioma diagnosis marker circ1:201817088|201817285 and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107937538B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205320B (en) * | 2019-06-18 | 2023-06-23 | 中国医科大学附属盛京医院 | lncRNA molecule linc00998 and application thereof in glioma treatment/prognosis evaluation |
-
2017
- 2017-12-28 CN CN201711454282.2A patent/CN107937538B/en active Active
Non-Patent Citations (2)
Title |
---|
RYBAK-WOLF ET AL.: "Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed.", 《MOLECULAR CELL》 * |
SALZMAN ET AL.: "Cell-Type Specific Features of Circular RNA Expression.", 《PLOS GENETICS》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110205320B (en) * | 2019-06-18 | 2023-06-23 | 中国医科大学附属盛京医院 | lncRNA molecule linc00998 and application thereof in glioma treatment/prognosis evaluation |
Also Published As
Publication number | Publication date |
---|---|
CN107937538B (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9868988B2 (en) | Method to assess human allograft status from microrna expression levels | |
EP3502269B1 (en) | Detection of brain cancer | |
CN107937532A (en) | Diagnosis of glioma marker hsa_circ_0021827 and application | |
CN107557472A (en) | Diagnosis of glioma mark circ9:135881633 | 135883078 and application | |
CN107937538A (en) | Diagnosis of glioma marker circ1:201817088 | 201817285 and application | |
CN109536502A (en) | A kind of PCR internal reference suitable for Trophoblastic Tumor blood plasma excretion body miRNA | |
CN107586843A (en) | Diagnosis of glioma mark circ7:100812747 | 100813208 and application | |
CN107619869A (en) | Diagnosis of glioma and prognostic marker circ16:85633914 | 85634132 and application | |
CN107586846A (en) | Diagnosis of glioma mark Circ3:129880309 | 129880559 and application | |
CN107604076A (en) | Diagnosis of glioma mark Circ6:4891713 | 4892379 and application | |
CN107937534A (en) | Diagnosis of glioma marker circ1:29154696 | 29154910 and application | |
CN107937529A (en) | Diagnosis of glioma marker hsa_circ_0135404 and application | |
CN107937540A (en) | Diagnosis of glioma marker circ17:47618350 | 47619164 and application | |
CN107557441B (en) | Glioma diagnosis marker Circ2:23823258|23823569 and application | |
CN107586845A (en) | Diagnosis of glioma mark Circ19:5604583 | 5604936 and application | |
CN107937528A (en) | Glioma prognostic marker hsa_circ_0125365 and application | |
CN107937543A (en) | Diagnosis of glioma marker circ10:72715111 | 72715902 and application | |
CN107586849A (en) | The circ9 in brain tissue source:4117768 | 4118881 application | |
CN107604073A (en) | Diagnosis of glioma mark circ22:42890947 | 42891182 and application | |
CN107937527A (en) | Diagnosis of glioma marker circ1:43920404 | 43920928 and application | |
CN107557474A (en) | Diagnosis of glioma mark circ15:98707562 | 98708107 and application | |
CN107937531A (en) | Diagnosis of glioma marker circ7:73686636 | 73687095 and application | |
CN107988368A (en) | Diagnosis of glioma marker circ9:33948374 | 33948587 and application | |
CN107604070A (en) | Diagnosis of glioma mark circ9:4117768 | 4118881 and application | |
CN107557473A (en) | Diagnosis of glioma mark circ6:79060478 | 79060818 and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |